ReNeuron Group plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNUGF research report →
About the company
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness.
- CEO
- Iain Gladstone Ross
- IPO
- 2007
- Employees
- 26
- HQ
- Pencoed, GB
Price Chart
- Market Cap
- $62.89K
- P/E
- -0.01
- P/S
- 0.09
- P/B
- 0.01
- EV/EBITDA
- 0.89
- Div Yield
- 0.00%
- Gross Margin
- -742.08%
- Op Margin
- -1342.45%
- Net Margin
- -1020.38%
- ROE
- -72.37%
- ROIC
- -105.51%
- Revenue
- $530.00K · 31.51%
- Net Income
- $-5,408,000 · 44.18%
- EPS
- $-0.09 · 44.29%
- Op Income
- $-7,115,000
- FCF YoY
- 0.12%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.05
- Avg Volume
- 328.072
Get TickerSpark's AI analysis on RNUGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RNUGF coverage
Recent articles, reports, and earnings notes.
No research on RNUGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNUGF report →Similar companies
Peers in the same neighborhood.